Turning Science into Business

Scientist pipetting in the lab
#Cellular assays #Drug discovery #Interview #Screening #Spinout #Turning Science into Business

Turning science into business: A step-change in adherent cell-based assays

Semarion was voted one of the SLAS2025 New Product Award winners. DDW’s Diana Spencer catches up with CEO and Co-founder Jeroen Verheyen to find out how the company has bridged the worlds of science and engineering.  DS: Congratulations on being one of the SLAS2025 New Product Award winners. How did… Read More

#Business & Investment #Exclusive Content

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

New DDW Highlights podcast: 10 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are… Read More

#News

#Business #Drug development #Drug discovery #Spinout #Start-ups #Turning Science into Business

This week in drug discovery (3-7 March) 

News round-up for 3-7 March by DDW Senior Digital Content Editor Diana Spencer. Our news round-up this week focuses on start-ups, the innovative fledgling companies that are coming through and sparking new life into various areas of drug discovery. The top stories: Start-up… Read More

#News

Cell therapy
#Cell therapy #Immunotherapy #Oncology #Solid tumours #T cell activation #Turning Science into Business

Are TILs the next big thing in cancer treatment?

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what's on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It's an autologous cell therapy, meaning cells are… Read More

#Cancer Research #Exclusive Content

RNA strand
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #CNS #Genetic diseases #mRNA #RNA #Turning Science into Business

Turning science into business: Amplifying mRNA by targeting regRNAs

DDW’s Diana Spencer speaks to Josh Mandel-Brehm, CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA… Read More

#Business & Investment #Exclusive Content

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #Gene editing #Lithuania #Turning Science into Business

Turning Science into Business: Commercialising CRISPR

While attending Life Science Baltics 2023, Diana Spencer spoke to Monika Paule, CEO and Co-founder of Caszyme, about creating a company based on CRISPR gene editing and some of the challenges of operating in this dynamic area of research. DS: What was the motivation for launching Caszyme and what challenges did… Read More

#Exclusive Content

Autophagy
#ALS #Autophagy #Healthspan #Neurodegenerative disorders #Parkinson's #Turning Science into Business

Turning Science into Business: Inducing autophagy to treat disease

DDW’s Diana Spencer speaks to Peter Hamley, Chief Scientific Officer of Samsara Therapeutics, to understand the role autophagy plays in neurodegenerative diseases and how boosting this process could increase healthspan. DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. What is… Read More

#Exclusive Content

Heart health concept
#Drug discovery #Heart attack #Regenerative Medicine #Stem cells #Turning Science into Business

Turning Science into Business: Can regenerative medicine treat heart attacks?   

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.   Based in France, CellProthera is a small, regenerative cell therapy developer that… Read More

#Exclusive Content

#Cancer research #Macomics #Macrophages #Omics #Oncology #Tumour microenvironment (TME) #Turning Science into Business

Turning science into business: Exploiting macrophage biology

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they… Read More

#Cancer Research #Exclusive Content

#Aptamer Group #Aptamers #Automation #Drug delivery #Gene delivery #Gene therapy #Molecular Biology #Oncology #Precision medicine #Turning Science into Business

Turning science into business: An optimised alternative to antibodies

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Atomic AI #Molecular Biology #RNA #Turning Science into Business

Turning science into business: Merging AI and RNA

New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. … Read More

#Exclusive Content #Start-up Zone